At the beginning of October, the range of medicines reimbursed by the Health Insurance Fund was expanded. Several new treatment options were added to the list of subsidized medicines, which, among other things, improve the availability of treatment for people suffering from serious and rare diseases.
Getter Hark, service manager for the Health Insurance Fund's drug reimbursement service, said that the additional drugs will account for nearly €800,000 of the total budget for existing drugs in the first year of reimbursement. "Medicines were added for the treatment of epilepsy, hypereosinophilic syndrome, chronic lymphocytic leukemia, the rare blood cancer Waldenström's macroglobulinemia, and heart muscle diseases. We also updated the conditions for adjuvant treatment of breast cancer, meaning that post-operative treatment is now available at an earlier stage, i.e. immediately after surgery," Hark listed.
One important change was the expansion of the conditions for prescribing mepolizumab, an active ingredient included in the list of subsidized drugs, and starting this month, the drug will be 100% reimbursed for the treatment of hypereosinophilic syndrome. "This is a very rare disease, with a prevalence of less than one case per 100,000 inhabitants. In Estonia, up to six patients are known to require treatment. Although the course of the disease varies from person to person, damage to the skin, lungs, digestive tract, and cardiovascular system is more common."
Symptomatic obstructive hypertrophic cardiomyopathy (OHCM) is a condition in which the walls of the left ventricle (ventricle) contract more strongly and become thicker than normal. Thickening of the heart wall can obstruct blood flow from the heart and make the heart muscle stiff. This obstruction hinders blood flow into and out of the heart and the pumping of blood throughout the body with each heartbeat.
According to Märt Elmet, a cardiologist at Tartu University Hospital, this rare disease can manifest itself at a younger age. The cause of the disease is usually a genetic predisposition. "Therefore, the disease cannot be prevented or treated by, for example, lifestyle changes. An early symptom of the disease is usually a decrease in exercise tolerance, which limits daily physical activity and significantly affects a person's quality of life. Ultimately, the disease can lead to heart failure, arrhythmias, and, in the worst case, sudden cardiac death."
Elmet noted that hypertrophic cardiomyopathy is one of the most common causes of sudden unexpected death in young people. In Estonia, cardiologists are monitoring approximately 70 patients with this disease. In order to help these people, the Health Insurance Fund will now finance the active ingredient mavacant (the drug Camzyos), which treats the root cause of the disease. Reimbursing the cost of the drug will cost the Health Insurance Fund nearly one million euros over the next few years.
As an alternative treatment option, funding will be provided for the drug Brukinsa, which is intended for the treatment of chronic lymphocytic leukemia. Its advantage over existing drugs is its greater safety and tolerability, especially in terms of human heart health. "Chronic lymphocytic leukemia is one of the most common forms of leukemia in the Western world, with an average annual incidence in Europe of 4.92 cases per 100,000 people. The average age at diagnosis is 72 years. The disease is incurable, so the main goal of treatment is to prolong the patient's life," explained Getter Hark.
The Health Insurance Fund now also reimburses the same drug for the treatment of Waldenström's macroglobulinemia. This is a slowly developing, rare and incurable form of blood cancer. The disease causes an increase in the level of certain proteins (immunoglobulin M) in the blood, which makes it thick. This, in turn, can cause bleeding, vision problems (such as blurred or double vision), headaches and dizziness, cramps, shortness of breath, and chest pain. The disease mainly affects elderly people, and the aim of treatment is to slow down the progression of the disease and alleviate the symptoms. In Estonia, an estimated five to seven patients will need treatment in the coming years, with the Health Insurance Fund financing their treatment at a cost of €150,000 per year.
Helps prevent breast cancer recurrence
In October, the Health Insurance Fund expanded the conditions for the use of Kisqali (ribociclib), a drug intended for the treatment of breast cancer. "Whereas previously the drug was only reimbursed for patients with advanced breast cancer, it is now also available for early-stage disease. The drug is suitable for the treatment of hormone receptor-positive and HER2-negative breast cancer, helping to prevent recurrence of the disease after surgery. In Estonia, approximately 53 patients require additional treatment in the first year after breast cancer surgery, up to 116 in the second year, and up to 204 in the third year," said Hark. By financing the drug, the Health Insurance Fund is investing nearly two million euros in people's well-being.
In addition, starting in October, the active ingredient lacosamide will be reimbursed to patients with epilepsy who have not responded to previous medications. "Epilepsy is a disease of the nervous system that causes sudden seizures, severely affecting a person's daily life, ability to work, and social functioning. People with this disease are two to three times more likely to die prematurely than the rest of the population. Although several epilepsy medications are available in Estonia, nearly one-third of patients remain drug-resistant throughout their lives and need alternative treatment, which the Health Insurance Fund now offers."
There are an estimated 6,300 people with epilepsy in Estonia, of whom around 150 patients per year may need lacosamide. The Health Insurance Fund contributes approximately €80,000 per year to the well-being of these people, taking into account that these patients also use other anti-epileptic drugs.
